LIVZON PHARMA (01513) announced that it has recently obtained a Drug Clinical Trial Approval Notice from the National Medical Products Administration. The approval, with notice number 2026LP01115, permits the company to conduct clinical trials for JP-1366 tablets. The trials will focus on the use of JP-1366 tablets in combination with appropriate antibiotics to eradicate Helicobacter pylori.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.